Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy
To date, diverse combination therapies with immune checkpoint inhibitors (ICIs), particularly oncolytic virotherapy, have demonstrated enhanced therapeutic outcomes in cancer treatment. However, high pre-existing immunity against the widely used adenovirus human serotype 5 (AdHu5) limits its extensi...
Main Authors: | Ping Zhou, Xuchen Wang, Man Xing, Xi Yang, Mangteng Wu, Hongyang Shi, Caihong Zhu, Xiang Wang, Yingying Guo, Shubing Tang, Zhong Huang, Dongming Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-06-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770522000596 |
Similar Items
-
Oncolytic Adenoviruses for Cancer Therapy
by: Lorella Tripodi, et al.
Published: (2021-03-01) -
Oncolytic Adenoviruses in Cancer Treatment
by: Ramon Alemany
Published: (2014-02-01) -
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
by: Praveensingh B. Hajeri, et al.
Published: (2020-06-01) -
Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models
by: Giulia Raimondi, et al.
Published: (2021-06-01) -
Adenovirus as a Vector and Oncolytic Virus
by: Wataru Matsunaga, et al.
Published: (2023-06-01)